Neurons News and Research

RSS

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Probiodrug AG (Probiodrug), a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer's disease (AD), today announced its scientists and academics collaborators published seminal findings on the role of pyroglu Aβ in AD pathology in the May 2, 2012 online edition of the journal Nature (DOI: 10.1038/nature11060). The new findings add to the growing body of evidence that pyroglu Aβ plays a crucial role in the initiation of AD. In addition, the research results further elucidate the mechanism by which pyroglu Aβ triggers neuronal toxicity.

3 May 2012

Grape-derived compound may prevent neurodegenerative disorders involving tau neuropathology

Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the basis for future investigations on how to prevent tau from damaging brain circuits involved in cognitive function.

2 May 2012

ASNTR honors UTMSH, MSU scientists with 2012 Sanberg awards

At the 19th Annual Conference of the American Society of Neural Therapy and Repair (ASNTR), held April 26 - 28 in Clearwater Beach, Florida, the ASNTR awarded The 2012 Bernard Sanberg Memorial Award for Brain Repair to Timothy J. Collier, PhD, professor of translational science and molecular medicine at Michigan State University and director of the Udall Center of Excellence in Parkinson's Disease Research at Michigan State University and the University of Cincinnati. ASNTR also presented The Molly and Bernard Sanberg Memorial Award to Sean I. Savitz, MD, associat

2 May 2012

Teenage risky behaviors can be traced to special brain wiring: Study

New research suggests that there is a complex networks of neurons in some youngsters’ brains that make them more likely to begin smoking, experimenting with cannabis or consuming large amounts of alcohol.

30 Apr 2012

Experimental drug for autism works effectively in laboratory mice: Study

A new experimental drug has shown promise in autism symptoms in mice. Researchers from the National Institutes of Mental Health and Pfizer reported Wednesday that an experimental compound, called GRN-529, increased social interactions and lessened repetitive self-grooming behavior in a strain of mice bred to display autism-like behaviors.

26 Apr 2012

Researchers identify new components of genetic pathway that controls neural stem cells

Can one feel too attached? Does one need to let go to mature? Neural stem cells have this problem, too. As immature cells, neural stem cells must stick together in a protected environment called a niche in order to divide so they can make all of the cells that populate the nervous system. But when it's time to mature, or differentiate, the neural stem cells must stop dividing, detach from their neighbors and migrate to where they are needed to form the circuits necessary for humans to think, feel and interact with the world.

26 Apr 2012

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine.

26 Apr 2012

Study shows how PCBs could add to autism risk

New research from UC Davis and Washington State University shows that PCBs, or polychlorinated biphenyls, launch a cellular chain of events that leads to an overabundance of dendrites - the filament-like projections that conduct electrochemical signals between neurons - and disrupts normal patterns of neuronal connections in the brain.

26 Apr 2012

UNC announces recipients of 12th Perl-UNC Neuroscience prize

The University of North Carolina at Chapel Hill has awarded the 12th Perl-UNC Neuroscience prize to Karl Deisseroth, MD, PhD of Stanford University and Edward Boyden, PhD and Feng Zhang, PhD of the Massachusetts Institute of Technology.

26 Apr 2012

Self-degradation response to antidepressant Zoloft observed in yeast cells

Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.

25 Apr 2012

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

U-M project to examine link between bipolar disorder and abnormalities in the circadian

A math professor at the University of Michigan will lead an international, $1 million project examining the links between bipolar disorder and abnormalities in the circadian, or daily, rhythms of a mammal's internal clock.

25 Apr 2012

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Neuron-killing pathology of AD requires presence of a-beta and elevated p-tau levels

According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau.

24 Apr 2012

Researchers develop small endoscopic device fitted with femtosecond laser scalpel

Whether surgeons slice with a traditional scalpel or cut away with a surgical laser, most medical operations end up removing some healthy tissue, along with the bad. This means that for delicate areas like the brain, throat, and digestive tract, physicians and patients have to balance the benefits of treatment against possible collateral damage.

24 Apr 2012

TopBP1 protein prevents early brain cells from DNA damage

St. Jude Children's Research Hospital scientists have rewritten the job description of the protein TopBP1 after demonstrating that it guards early brain cells from DNA damage. Such damage might foreshadow later problems, including cancer.

24 Apr 2012

HDAC6 protein may provide novel target for stress-linked disorders

A cellular protein called HDAC6, newly characterized as a gatekeeper of steroid biology in the brain, may provide a novel target for treating and preventing stress-linked disorders, such as depression and post-traumatic stress disorder (PTSD), according to research from the Perelman School of Medicine at the University of Pennsylvania.

24 Apr 2012

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Something in the world of medicine is seriously amiss. Unhappy patients gripe about their doctors' brusque manner and give them bad marks on surveys and consumer websites like HealthGrades and Angie's List. They tell tales of being rushed out of the office by harried doctors who miss crucial diagnoses, never look up from their computers during an exam, make errors in prescriptions, and just plain don't listen to their patients. ... And things don't seem much better from the other side of the stethoscope.

20 Apr 2012

Neurons News and Research

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Grape-derived compound may prevent neurodegenerative disorders involving tau neuropathology

ASNTR honors UTMSH, MSU scientists with 2012 Sanberg awards

Teenage risky behaviors can be traced to special brain wiring: Study

Experimental drug for autism works effectively in laboratory mice: Study

Researchers identify new components of genetic pathway that controls neural stem cells

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

Study shows how PCBs could add to autism risk

UNC announces recipients of 12th Perl-UNC Neuroscience prize

Self-degradation response to antidepressant Zoloft observed in yeast cells

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

U-M project to examine link between bipolar disorder and abnormalities in the circadian

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

Neuron-killing pathology of AD requires presence of a-beta and elevated p-tau levels

Researchers develop small endoscopic device fitted with femtosecond laser scalpel

TopBP1 protein prevents early brain cells from DNA damage

HDAC6 protein may provide novel target for stress-linked disorders

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Neuroscience - Second Edition eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News